Targeted Protein Degradation (PROTACs)

Targeted Protein Degradation (PROTACs)

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Targeted Protein Degradation (PROTACs)</th>
</tr>
<tr>
<td class="label">Program</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ARV-102</td>
<td>LRRK2</td>
</tr>
<tr>
<td class="label">Tau PROTAC</td>
<td>[tau protein](/proteins/tau)</td>
</tr>
<tr>
<td class="label">α-Syn PROTAC</td>
<td>alpha-synuclein</td>
</tr>
<tr>
<td class="label">mHTT PROTAC</td>
<td>Mutant huntingtin</td>
</tr>
<tr>
<td class="label">Dual PROTAC T3</td>
<td>Tau + α-Syn</td>
</tr>
</table>

Targeted Protein Degradation (Protacs) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Targeted Protein Degradation (PROTACs)

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Targeted Protein Degradation (PROTACs)</th>
</tr>
<tr>
<td class="label">Program</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ARV-102</td>
<td>LRRK2</td>
</tr>
<tr>
<td class="label">Tau PROTAC</td>
<td>[tau protein](/proteins/tau)</td>
</tr>
<tr>
<td class="label">α-Syn PROTAC</td>
<td>alpha-synuclein</td>
</tr>
<tr>
<td class="label">mHTT PROTAC</td>
<td>Mutant huntingtin</td>
</tr>
<tr>
<td class="label">Dual PROTAC T3</td>
<td>Tau + α-Syn</td>
</tr>
</table>

Targeted Protein Degradation (Protacs) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Targeted protein degradation (TPD) using proteolysis-targeting chimeras (PROTACs) and related technologies represents a paradigm-shifting therapeutic approach for [neurodegenerative diseases](/diseases). Unlike traditional small-molecule inhibitors that block protein function, PROTACs recruit the cell's own [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) to selectively destroy disease-causing proteins, including tau], [alpha-synuclein](/proteins/alpha-synuclein), mutant [huntingtin](/proteins/huntingtin), and [LRRK2](/proteins/lrrk2-protein)[@sakamoto2001] [@bekes2022]
</a>. [@arvinas2025]

PROTACs are heterobifunctional molecules consisting of three elements: (1) a ligand that binds the target protein (warhead), (2) a ligand that recruits an E3 ubiquitin ligase, and (3) a chemical linker connecting the two. By bringing the target protein into proximity with an E3 ligase, PROTACs trigger polyubiquitination and subsequent proteasomal degradation of the target["@bekes2022"] [@arvinas2025a]
</a>. [@arvinas]

This approach offers several advantages over conventional therapeutics for neurodegeneration: the ability to eliminate toxic protein species entirely rather than merely inhibiting their activity; catalytic mechanism of action where a single PROTAC molecule can degrade multiple target proteins; and the capacity to target proteins previously considered "undruggable" by traditional pharmacology. As of 2025, the LRRK2 degrader ARV-102 has become the first PROTAC to demonstrate blood-brain barrier penetration and central target engagement in humans, marking a milestone for the field["@arvinas2025"] [@gao2024]
</a>. [@xu2025]

Mechanism of Action

The Ubiquitin-Proteasome Pathway

PROTACs hijack the cell's natural protein disposal system. The [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) is the primary pathway for selective protein degradation in eukaryotic cells: [@ding2024]

PROTACs exploit step 3 by artificially bringing any target protein into the proximity of an E3 ligase, inducing its ubiquitination and degradation regardless of the target's normal biology[@bekes2022]. [@green2025]

E3 Ligase Recruitment

Two E3 ligases dominate current PROTAC design: [@poso2025]

• Cereblon (CRBN): Recruited by thalidomide-derived ligands (lenalidomide, pomalidomide). Cereblon-recruiting PROTACs have shown success for CNS targets due to favorable drug-like properties.
• VHL (Von Hippel-Lindau): Recruited by hydroxyproline-based ligands. VHL-recruiting PROTACs often achieve higher selectivity but may have more limited CNS penetration.

Catalytic Degradation

A key advantage of PROTACs is their catalytic mechanism: after inducing degradation of one target molecule, the PROTAC is released and can engage another target. This means sub-stoichiometric concentrations of the PROTAC can achieve near-complete target elimination, potentially reducing dosing requirements and off-target effects compared to occupancy-driven inhibitors[@sakamoto2001]
</a>.

Neurodegenerative Disease Applications

LRRK2 Degradation (Parkinson's Disease)

[LRRK2](/proteins/lrrk2-protein) (leucine-rich repeat kinase 2) mutations are the most common genetic cause of familial [Parkinson's disease](/diseases/parkinsons-disease), and elevated LRRK2 kinase activity is also implicated in idiopathic PD. While [LRRK2 inhibitors](/therapeutics/lrrk2-inhibitors) reduce kinase activity, PROTAC-mediated degradation eliminates all LRRK2 functions, including scaffolding and protein-protein interaction roles that kinase inhibitors cannot address.

ARV-102 (Arvinas)

ARV-102 is the most clinically advanced PROTAC for neurodegeneration — an orally bioavailable, brain-penetrant PROTAC targeting LRRK2 for degradation.

Preclinical results:

• In non-human primates, orally administered ARV-102 reached deep-brain regions and degraded LRRK2 by nearly 90%
• Demonstrated dose-dependent, sustained LRRK2 degradation in both brain and peripheral tissues[@arvinas2025]

Phase 1 clinical results (2025):

• First-in-human dosing initiated in February 2024
• Positive Phase 1 data presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders
• Demonstrated blood-brain barrier penetration — confirmed by CSF drug levels
• Achieved central and peripheral LRRK2 degradation in healthy volunteers
• Well tolerated with no serious adverse events[@arvinas2025a]

Development plan: Pending Phase 1 multiple-dose data and IND clearance, Arvinas intends to initiate a Phase 1b trial in patients with [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) in the first half of 2026, with potential expansion to Parkinson's Disease.

Tau Degradation (Alzheimer's Disease and Tauopathies)

[Tau](/proteins/tau) pathology — including hyperphosphorylation, aggregation, and [prion-like spreading](/mechanisms/prion-like-spreading) — is the pathological hallmark most closely correlated with cognitive decline in [Alzheimer's disease](/diseases/alzheimers-disease) and other [tauopathies](/mechanisms/tauopathies). PROTACs offer the unique ability to degrade multiple pathological tau species.

Arvinas tau PROTAC program: Preclinical studies have demonstrated that tau-targeting PROTACs can degrade several different forms of tau, including phosphorylated tau species (p-tau181, [p-tau217](/biomarkers/p-tau-217), p-tau231), resulting in reduced insoluble aggregated tau in mouse tauopathy models[@arvinas]
</a>.

Dual PROTACs: Researchers have developed dual-targeting PROTACs capable of simultaneously degrading both [alpha-synuclein](/proteins/alpha-synuclein) aggregates and total tau. Lead compound T3 achieved degradation efficiency DC50 values of 1.57 μM for [alpha-synuclein](/proteins/alpha-synuclein) aggregates and 4.09 μM for total tau, demonstrating the feasibility of multi-target degradation[@gao2024]
</a>.

Key advantages over anti-tau antibodies: Unlike tau-targeted therapeutics](/therapeutics/tau-targeted-therapeutics) based on antibodies (e.g., semorinemab, bepranemab), PROTACs are small molecules that can be administered orally and potentially achieve intracellular target engagement — critical because most pathological tau is intracellular.

alpha-synuclein Degradation (Parkinson's Disease, DLB)

[alpha-synuclein](/proteins/alpha-synuclein) aggregation into Lewy bodies and Lewy neurites is the pathological hallmark of [Parkinson's disease](/diseases/parkinsons-disease), [Lewy body dementia](/diseases/lewy-body-dementia), and [multiple system atrophy](/diseases/multiple-system-atrophy). [alpha-synuclein](/proteins/alpha-synuclein) PROTACs aim to clear both soluble oligomeric and fibrillar forms.

Researchers have developed PROTACs built on pyrrolopyridine-based anchors that selectively bind alpha-synuclein while recruiting cereblon or VHL E3 ligases. Dose-response experiments have demonstrated DC50 values in the low nanomolar range with degradation approaching 80% for lead molecules[@gao2024]
</a>.

Mutant Huntingtin Degradation (Huntington's Disease)

Mutant [huntingtin](/proteins/huntingtin) (mHTT) with expanded polyglutamine repeats forms toxic aggregates in [Huntington's disease](/mechanisms/huntington-pathway). PROTACs targeting mHTT offer the potential for selective degradation of the mutant protein while sparing wild-type [huntingtin](/proteins/huntingtin), which retains important cellular functions.

Recent advances:

• PROTACs have been developed that selectively degrade aggregated mHTT without affecting wild-type [huntingtin](/proteins/huntingtin-protein)
• In cellular models, these compounds significantly reduced mHTT-induced cytotoxicity
• In the R6/2 HD mouse model, continuous PROTAC delivery improved body weight, motor coordination, and survival, correlating with reduced mHTT aggregation[@xu2025]

This selectivity advantage distinguishes PROTACs from [antisense oligonucleotide therapies](/therapeutics/antisense-oligonucleotide-therapies) like tominersen, which reduce both mutant and wild-type [huntingtin](/genes/htt).

TDP-43 and FUS (ALS/FTD)

[TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) characterizes approximately 97% of [ALS](/diseases/amyotrophic-lateral-sclerosis) and ~50% of [FTD](/diseases/frontotemporal-dementia) cases. PROTACs targeting mislocalized or aggregated [TDP-43](/proteins/tdp-43) are in early preclinical development. Similarly, PROTACs targeting [FUS](/entities/fus) aggregates are being explored for FUS-related ALS/FTD.

Related Technologies

Molecular Glues

Molecular glues are small molecules that stabilize protein-protein interactions between a target protein and an E3 ligase, inducing target degradation. Unlike bifunctional PROTACs, molecular glues are monovalent compounds that create a neo-interface, typically offering:

• Smaller molecular weight (better drug-like properties and CNS penetration)
• Novel binding modes not accessible to PROTACs
• Discovery often through serendipity or focused screening

Lysosome-Targeting Chimeras (LYTACs)

LYTACs redirect extracellular and membrane proteins to lysosomes for degradation via the lysosomal pathway, complementing intracellular PROTACs. They consist of a target-binding moiety conjugated to a lysosome-targeting receptor ligand (e.g., mannose-6-phosphate). LYTACs may be particularly useful for degrading extracellular aggregates of [amyloid-beta](/proteins/amyloid-beta) or secreted alpha-synuclein.

Autophagy-Targeting Chimeras (AUTACs)

AUTACs direct target proteins to autophagosomes for degradation, leveraging the autophagic pathway rather than the proteasome. This approach is especially relevant for protein aggregates that are too large for proteasomal degradation — a common situation in neurodegenerative diseases where large fibrils and inclusions accumulate.

Antibody-Based Degraders (AbTACs)

AbTACs use bispecific antibodies to recruit membrane-bound E3 ligases (e.g., RNF43) to cell-surface target proteins, inducing their endocytosis and lysosomal degradation. This technology extends TPD to membrane proteins and extracellular targets.

Challenges for CNS Applications

Blood-Brain Barrier Penetration

PROTACs are typically larger molecules (700-1000 Da) than conventional small-molecule drugs, making blood-brain barrier ([BBB](/entities/blood-brain-barrier) penetration a significant challenge. ARV-102's demonstrated CSF penetration in humans is a critical proof-of-concept for CNS-targeted PROTACs[@arvinas2025]
</a>.

Strategies to improve [BBB](/entities/blood-brain-barrier) penetration include:

• Optimizing physicochemical properties (lipophilicity, molecular weight, hydrogen bond donors/acceptors)
• Prodrug approaches
• Nanoparticle or exosome delivery systems
• Focused ultrasound-mediated BBB opening ([focused ultrasound](/therapeutics/focused-ultrasound)

Target Selectivity

For proteins with disease-relevant and essential normal functions (e.g., wild-type huntingtin, normal tau, selective degradation of pathological forms while sparing physiological protein is crucial. Approaches include:

• Conformation-selective warheads that preferentially bind aggregated or post-translationally modified (e.g., hyperphosphorylated) forms
• Tissue-specific E3 ligase recruitment
• Context-dependent degradation (e.g., only in cells with high target levels)

Hook Effect

At very high concentrations, PROTACs can saturate both the target protein and E3 ligase separately, preventing ternary complex formation — the "hook effect." This creates an inverted U-shaped dose-response curve that must be considered in clinical dosing[@bekes2022].

Resistance Mechanisms

Cells may develop resistance to PROTACs through:

• Mutations in the target protein's PROTAC-binding site
• Downregulation or mutation of the recruited E3 ligase
• Upregulation of deubiquitinating enzymes (DUBs)
• Impairment of proteasome function

Aggregate Targeting

Large protein aggregates (fibrils, inclusions) cannot be processed by the 26S proteasome and may require [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)-based degradation approaches (AUTACs) rather than classical PROTACs. Developing degraders that target both soluble and aggregated forms remains an active area of research.

Clinical Development Landscape

Future Directions

The field of targeted protein degradation for neurodegeneration is evolving rapidly:

• Oral brain-penetrant degraders: ARV-102's success provides a template for developing additional CNS-penetrant PROTACs
• Multi-target degraders: Dual PROTACs that simultaneously target multiple disease proteins may address the co-pathology common in neurodegeneration
• Combination with other modalities: PROTACs combined with [immunotherapy](/therapeutics/immunotherapy), [gene therapy](/therapeutics/gene-therapy), or [autophagy enhancers](/therapeutics/autophagy-enhancing-therapies) may offer synergistic disease modification
• Biomarker-guided development: Using CSF and plasma biomarkers (p-tau, [NfL](/proteins/nfl-protein), alpha-synuclein seed amplification) to demonstrate target engagement and disease modification in clinical trials
• Patient stratification: Genetic testing (e.g., LRRK2 mutation status) to identify patients most likely to benefit from specific degraders

See Also

• [alpha-synuclein Immunotherapy](/therapeutics/alpha-synuclein-immunotherapy)
• [Antisense Oligonucleotide (ASO) Therapy in Neurodegeneration](/therapeutics/antisense-oligonucleotide-therapy)
• [Autophagy-Enhancing Therapies](/therapeutics/autophagy-enhancing-therapies)
• [LRRK2 Kinase Inhibitors](/therapeutics/lrrk2-inhibitors)
• [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)](/content/therapeutics)

External Links

• [Arvinas Neuroscience Pipeline](https://www.arvinas.com/research-and-development/neuroscience/)
• [Targeted Protein Degradation Consortium](https://www.thesgc.org/tpd)

Background

The study of Targeted Protein Degradation (Protacs) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Emerging E3 Ligases for CNS Applications

While CRBN and VHL dominate current PROTAC design, emerging E3 ligases offer opportunities for improved brain penetration and tissue selectivity:

DCAF15

RNF4

Novel Cereblon Modulators

Recent Clinical Advances (2025-2026)

The field has seen significant clinical momentum:

• ARV-102 Phase 1b plans: Following positive Phase 1 data, Arvinas plans to initiate patient trials in PSP and PD in 2026
• First tau PROTAC IND: Expected submission from a major pharmaceutical company in 2026
• Industry partnerships: Multiple pharma companies have established PROTAC discovery programs for CNS targets through partnerships and acquisitions[@pharma2025]

Regulatory Considerations

PROTACs represent a novel modality requiring specialized regulatory pathways:

• FDA and EMA have established working groups for TPD therapeutics
• Unique safety considerations include off-target degradation, E3 ligase biology, and long-term effects of protein knockdown
• Biomarker requirements for CNS target engagement are well-defined (CSF, PET ligands)[@fda2024]

Conclusion

PROTACs and related degradation technologies represent a transformative approach for neurodegenerative disease therapy. The demonstration of brain penetration and target engagement with ARV-102 in 2025 marks a critical milestone, paving the way for multiple clinical candidates targeting tau, alpha-synuclein, TDP-43, and mutant huntingtin. Challenges remain around improving brain delivery, achieving selective degradation of pathological protein species, and establishing long-term safety profiles, but the therapeutic potential of completely eliminating disease-causing proteins justifies continued investment in this modality.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: MCOLN1
• [Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: IGF2R
• [Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: CHMP2B
• [Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: RAB7A
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
• [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4
• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE

Related Analyses:

• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;